These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35903011)

  • 61. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.
    Eliakim-Raz N; Robenshtok E; Shefet D; Gafter-Gvili A; Vidal L; Paul M; Leibovici L
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD004418. PubMed ID: 22972070
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
    Martinez FJ
    Clin Infect Dis; 2004 May; 38 Suppl 4():S328-40. PubMed ID: 15127366
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease.
    Threapleton CJ; Janjua S; Fortescue R; Baker EH
    Cochrane Database Syst Rev; 2019 May; 5(5):CD013024. PubMed ID: 31125127
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of glucocorticoids for the treatment of macrolide refractory mycoplasma pneumonia in children: meta-analysis of randomized controlled trials.
    Kim HS; Sol IS; Li D; Choi M; Choi YJ; Lee KS; Seo JH; Lee YJ; Yang HJ; Kim HH
    BMC Pulm Med; 2019 Dec; 19(1):251. PubMed ID: 31852460
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia.
    Shorr AF; Zadeikis N; Xiang JX; Tennenberg AM; Wes Ely E
    Clin Ther; 2005 Aug; 27(8):1251-9. PubMed ID: 16199249
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials.
    Khan AS; Iqbal A; Muhammad AA; Mazhar F; Lodhi MF; Ahmed KF; Kumar S; Varrassi G; Khatri M
    Cureus; 2023 Apr; 15(4):e37650. PubMed ID: 37200652
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis.
    Hagberg L; Carbon C; van Rensburg DJ; Fogarty C; Dunbar L; Pullman J
    Respir Med; 2003 Jun; 97(6):625-33. PubMed ID: 12814146
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
    Fogarty CM; Greenberg RN; Dunbar L; Player R; Marrie TJ; Kojak CM; Morgan N; Williams RR
    Clin Ther; 2001 Mar; 23(3):425-39. PubMed ID: 11318077
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
    Teh B; Grayson ML; Johnson PD; Charles PG
    Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparing Several Treatments with Antibiotics for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li X
    Iran J Public Health; 2021 Jun; 50(6):1108-1119. PubMed ID: 34540732
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Meta-analysis of fluoroquinolones versus macrolides for treatment of legionella pneumonia.
    Kato H; Hagihara M; Asai N; Shibata Y; Koizumi Y; Yamagishi Y; Mikamo H
    J Infect Chemother; 2021 Mar; 27(3):424-433. PubMed ID: 33268272
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Community-Acquired Pneumonia in Adults: Diagnosis and Management.
    Kaysin A; Viera AJ
    Am Fam Physician; 2016 Nov; 94(9):698-706. PubMed ID: 27929242
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis.
    Dimopoulos G; Matthaiou DK; Karageorgopoulos DE; Grammatikos AP; Athanassa Z; Falagas ME
    Drugs; 2008; 68(13):1841-54. PubMed ID: 18729535
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Head-to-head trials of antibiotics for bronchiectasis.
    Kaehne A; Milan SJ; Felix LM; Sheridan E; Marsden PA; Spencer S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD012590. PubMed ID: 30184243
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interventions for bacterial folliculitis and boils (furuncles and carbuncles).
    Lin HS; Lin PT; Tsai YS; Wang SH; Chi CC
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013099. PubMed ID: 33634465
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical efficacy of moxifloxacin versus comparator therapies for community-acquired pneumonia caused by Legionella spp.
    Garau J; Fritsch A; Arvis P; Read RC
    J Chemother; 2010 Aug; 22(4):264-6. PubMed ID: 20685631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.